Achilles Therapeutics 6-K Report: Asset Sale to AstraZeneca & Strategic Update

Here's a summary of the key information extracted from the provided financial report section (Form 6-K) for Achilles Therapeutics plc:

1. Filing Details:

• Type: 6-K
• Commission File Number: 001-40299
• Filing Date: December 26, 2024

2. Company Information:

• Name: Achilles Therapeutics plc
• Address: 245 Hammersmith Road, London W6 8PW, United Kingdom
• Contact: Tel: +44 (0)20 8154 4600

3. Key Announcement:

• On December 24, 2024, Achilles Therapeutics plc issued a press release regarding:
• • The sale of technology assets to AstraZeneca.
  • A strategic update related to the company.

4. Exhibits:

• The press release is included as Exhibit 99.1 in this report.

5. Incorporation by Reference:

• The report is incorporated by reference into the company’s filings under the Securities Act of 1933, including specific Registration Statements on Forms F-3 and S-8.

6. Signatory:

• The report was signed by Robert Coutts, Chief Financial Officer, as of December 26, 2024.

Insights:

• The sale of technology assets to AstraZeneca indicates a potential strategic shift or focus for Achilles Therapeutics, possibly allowing them to leverage resources or expertise from a larger pharmaceutical partner.
• The strategic update may provide insights into the company's future direction, although further details would likely be available in the referenced press release (Exhibit 99.1).
• The filing is part of the company's compliance as a foreign private issuer, suggesting they are adhering to SEC regulations for disclosures.

This summary covers the most critical aspects of the report, reflecting significant corporate actions and compliance details.